Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 31, Issue 6, pp 442–444 | Cite as

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy

  • Stefan C. Grant
  • Mark G. Kris
  • Richard J. Gralla
  • Rebecca A. Clark
  • Leslie B. Tyson
Original Articles Dazopride, Antiemetic, Benzamide

Summary

Dazopride, a substituted benzamide structurally related to metoclopramide, is a potent gastric prokinetic agent that prevents cisplatin-induced emesis in animals. Unlike metoclopramide, dazopride has no effect on dopamine receptors and therefore should not produce extrapyramidal side effects. In this dose-ranging trial, 23 patients with cancer receiving chemotherapy known to produce nausea and vomiting received three i.v. infusions of dazopride every 2 h beginning 30 min before the chemotherapy. Seven dose levels were explored ranging from 0.5 to 4.0 mg/kg in each of the three infusions. Toxicities were mild and included sedation, dizziness, visual disturbances, and headaches. All side effects were transient and were not dose-related. Antiemetic effects were observed. Dazopride can be safely given on this schedule at doses of up to 4.0 mg/kg to patients receiving chemotherapy. On the basis of the results of this trial, further studies of this agent are warranted.

Keywords

Dopamine Cancer Research Dose Level Dopamine Receptor Metoclopramide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allan SG, Cornbleet MA, Warrington PS, Golland IM, Leonard RC, Smyth JN (1984) Dexamethasone and high dose metoclopramide: efficacy in controlling. BMJ [Clin Res] 289:878Google Scholar
  2. 2.
    Allen JC, Gralla R Reilly L, Kellick M, Young C (1985) Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 3:1136Google Scholar
  3. 3.
    Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, Johnson DN, Sancilio LF, Ward JW (1986) Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. Dig Dis Sci 31:524Google Scholar
  4. 4.
    Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nobria V, Owera AJB, Simpson KM, Tan CC, Tattersall D (1987) The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology 26:669Google Scholar
  5. 5.
    Costall B, Domeney AM, Naylor RJ, Tattersall FD (1987) Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology 26:1321Google Scholar
  6. 6.
    Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat Rep 66:187Google Scholar
  7. 7.
    Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905Google Scholar
  8. 8.
    Grunberg SM, Ehler E, McDermed JE, Akerley WL (1988) Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst 80:864Google Scholar
  9. 9.
    Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G, et al. (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy [see comments]. J Clin Oncol 9:721Google Scholar
  10. 10.
    Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, Reilly LK (1983) Extrapyramidal reactions with high-dose metoclopramide (letter). N Engl J Med 309:433Google Scholar
  11. 11.
    Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S (1987) Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60:2816Google Scholar
  12. 12.
    Kris MG, Gralla RJ, Clark RA, Tyson LB (1988) Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6:659Google Scholar
  13. 13.
    Kris MG, Gralla RJ, Clark RA, Tyson LB (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42Google Scholar
  14. 14.
    Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED (1984) Antiemetic efficacy of dexamethasone. Randomized double-blind crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311:549Google Scholar
  15. 15.
    McCallum RW (1985) Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 80:1008Google Scholar
  16. 16.
    Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, et al. (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Stefan C. Grant
    • 1
  • Mark G. Kris
    • 1
  • Richard J. Gralla
    • 1
  • Rebecca A. Clark
    • 1
  • Leslie B. Tyson
    • 1
  1. 1.Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of MedicineMemorial Sloan-Kettering Cancer Center and Cornell University Medical CollegeNew YorkUSA

Personalised recommendations